Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Annual zoledronic acid for postmenopausal osteoporosis
2004-000638-35Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postmenopausal osteoporosis comparing Zoledronic acid 5 mg i.v with Placebo i.v (2 arms). Primary endpoint: Change of BMD at the lumbar spine at Month 24. Started Jul 2004; status: completed.
02
Drugs
zoledronic acid
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on 2004-000638-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000638-35.